Tarix Orphan receives Orphan Drug Status for TXA127 from FDA

Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to TXA127, the company’s prospective treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.

Tarix Orphan has also announced a partnership with DEBRA Austria to further develop TXA127 as a potential RDEB treatment.

"RDEB is a devastating disease with no currently approved therapies and treatment limited to supportive care," DEBRA Austria CEO Dr. Rainer Riedl said. "We are pleased to support this work with Tarix Orphan in hopes of demonstrating the potential of TXA127 as a means of slowing or halting the debilitating tissue damage that accrues with progression of RDEB. Our commitment to research is to develop not only treatments that address the underlying genetic causes of EB but, equally, treatments that address the incapacitating consequences: reducing scarring and contractures that result from chronic wounds would greatly improve quality of life for people with RDEB. This study to be undertaken by the research group led by Prof. Leena Bruckner-Tuderman at the University of Freiburg will continue our support for their valuable work combatting fibrosis in EB, and we are delighted to do so."